OptimizeRx - OPRX Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OptimizeRx in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OPRX shares.
View OPRX analyst ratings or view top-rated stocks.

5 brokers have issued 12-month price objectives for OptimizeRx's shares. Their OPRX share price forecasts range from $16.00 to $76.00. On average, they expect the company's stock price to reach $41.00 in the next twelve months. This suggests a possible upside of 114.7% from the stock's current price.
View analysts price targets for OPRX or view top-rated stocks among Wall Street analysts.

OptimizeRx's stock was trading at $16.80 at the beginning of the year. Since then, OPRX stock has increased by 13.7% and is now trading at $19.10.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our OPRX earnings forecast.

OptimizeRx Co. (NASDAQ:OPRX) announced its earnings results on Tuesday, November, 8th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.02. The company earned $15.09 million during the quarter, compared to analyst estimates of $15.16 million. OptimizeRx had a negative net margin of 16.62% and a negative trailing twelve-month return on equity of 6.68%.

OptimizeRx issued an update on its FY 2022 earnings guidance on Thursday, December, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $62.00 million-$68.00 million, compared to the consensus revenue estimate of $64.05 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other OptimizeRx investors own include InterDigital (IDCC), Bank of Hawaii (BOH), NVIDIA (NVDA), STAG Industrial (STAG), Etsy (ETSY), Marvell Technology (MRVL), Trade Desk (TTD), Verizon Communications (VZ), Advanced Micro Devices (AMD) and Amgen (AMGN).

OptimizeRx trades on the NASDAQ under the ticker symbol "OPRX."

OptimizeRx's stock is owned by many different institutional and retail investors. Top institutional shareholders include Kornitzer Capital Management Inc. KS (1.75%), Rice Hall James & Associates LLC (1.58%), Greenwood Capital Associates LLC (0.28%), Wesbanco Bank Inc. (0.10%), Yousif Capital Management LLC (0.07%) and Comerica Bank (0.06%). Insiders that own company stock include Douglas P Baker, Douglas P Baker, Edward Stelmakh, Ellen O'connor Vos, Gregory D Wasson, James Paul Lang, Marion Odence-Ford, Miriam J Paramore, Patrick D Spangler, Stephen L Silvestro, Stephen L Silvestro and William J Febbo.
View institutional ownership trends.

Shares of OPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OPRX stock can currently be purchased for approximately $19.10.

OptimizeRx (NASDAQ:OPRX) has a market capitalization of $327.57 million and generates $61.29 million in revenue each year. The company earns $380,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis.

OptimizeRx's mailing address is 400 WATER STREET SUITE 200, ROCHESTER MI, 48307. The official website for the company is www.optimizerx.com. The company can be reached via phone at (248) 651-6568, via email at oprx@cma.team, or via fax at 248-453-5529.